- FR
- EN
3743
-
-
-
-
Communiqué de presseRevue 2024 des hypothèses L&H achevée, ratio de solvabilité Groupe de 203 %
-
Articles d'experts12 novembre 2024How consumer groups, patient representatives, and the insurance industry are working in partnership to help protect cancer survivors
-
-
Articles d'experts31 octobre 2024Using Pandemic Mortality Experience for Pricing Longevity
-
Actualités25 octobre 2024Winner of the 2024 Most Innovative Product/Service Award - General Insurance
-
Drugs developed for the treatment of diabetes such as semaglutide (marketed as Ozempic or Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro or Zepbound) are being used to decrease the weight of obesity risks:
-
-
Nos expertsJulien joined SCOR Alternative Solutions in 2022, as an underwriter, working for corporates clients in the EMEA region, and also contributing to the advisory, analytics within the team.
-
